Broad participation of Barcelona Science Park at BioSpain 2016 Blog Post

The Bilbao Exhibition Center (BEC) in Barakaldo (Bizkaia) will host  BioSpain 2016, the 8th edition of the eighth edition of this biennial event of biotechnology, the largest in Europe with permanent headquarters in one country and the fifth in the world ranking by number of partnering meetings. The event, to be held from 28 to 30 September, will bring together more than 2,000 attendees, 855 companies and nearly 50 investors- and will feature the participation of the Barcelona Science Park (PCB) and a large number of companies and entities of the PCB Community.

 

The genetic history of Aboriginal Australians Blog Post

The CNAG, based at Barcelona Science Park, participates in a study that analyses the genome of the Aboriginal Australian population that will help to understand how modern humans left the African continent. The findings of this study are published in Nature. The CNAG reseacher Òscar Lao, leader of the Population Genomics team, is first co-author of this work and contributed to the study analysing and interpreting the sub-populations of Aboriginal Australians. The debate over whether anatomically modern humans left the African continent in one or several waves is very intense in this Nature edition.

 

New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease Blog Post

Scientists from the Institute for Research in Biomedicine (IRB Barcelona) at Barcelona Science Park (PCB), in collaboration with researchers at Scientific and Technological Centers of the University of Barcelona (CCiTUB), the University of Leuven (Belgium) and the University of Groningen (the Netherlands), and the the, describes for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane. Interpreted in the context of Alzheimer´s disease, this discovery suggests that the aggregate can also perforate the membrane of neurons, alter the equilibrium of these cells, and trigger their death.

 

David Bermúdez, new CEO of Intelligent Pharma Blog Post

Engineer, David Bermúdez, until now Director of Technology at Intelligent Pharma, has been appointed CEO of this biotech located at the Barcelona Science Park (PCB). Bermúdez takes on this new challenge as of the 1st September and brings nearly twenty years of professional experience in research, development and leadership of innovative interdisciplinary projects in the field of ICT, artificial intelligence, supercomputing and drug design.

 

Two proteins safeguard skin stem cells Blog Post

A study led by ICREA researcher Salvador Aznar Benitah and undertaken at the Institute for Research in Biomedicine (IRB Barcelona) based at PCB has identified two proteins that are fundamental to conserve skin stem cells and has shown that without these proteins these cells are lost. The study, which has been published in Cell Stem Cell, has involved Luciano Di Croce’s group at the Center for Genomic Regulation (CRG).

 

The 15th edition of the Summer in the Park! starts Blog Post

The welcome ceremony to participants of the Spend the summer at the Park! program was held tyesterday, Monday, July 18. The aim of this initiative –organized annually by the Barcelona Science Park (PCB)– is to bring research closer to students of any university in the world through their participation in projects currently being carried out in research groups, research centers and companies based at the PCB.

 

Launch of Biodiscovery, a spin-off from IRB Barcelona and the BSC-CNS to speed up drug discovery Blog Post

This morning in Barcelona, the Institute for Research in Biomedicine (IRB Barcelona) –based at Barcelona Science Park (PCB)–  and the Barcelona Supercomputing Center-National Supercomputing Center (BSC-CNS) have presented Nostrum Biodiscovery, a new biotech company that applies computational simulation to help new drugs and biotech molecules to reach the market. The creation of this spin-off has also been made possible thanks to the Bosch i Gimpera Foundation (FBG) of the University of Barcelona (UB) and the Catalan Institute for Research and Advanced Studies (ICREA), with the support by the Botín Foundation’s technology transfer programme.

 

The sperm tail may determine semen quality Blog Post

The annual Congress of the European Society of Human Reproduction and Embryology (ESHRE) has been the setting chosen by the Eugin group and the Centre for Genomic Regulation (CRG) to present new collaborative research. The study describes, for the first time, the presence of alterations in the tail of the human sperm, the so called flagellum, which will help indicate the quality of sperm and improve the diagnosis of infertility.

 

Avizorex Pharma submits Clinical Trial Application for its lead compound AVX-012 for Dry Eye Syndrome Blog Post

Avizorex Pharma –an ophthalmology biotech company with offices at Barcelona Science Park (PCB)– announces the submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, requesting clearance to initiate a Phase I/II clinical trial investigating the use of AVX-012 Ophthalmic Solution, a small molecule with a novel mechanism of action to treat patients suffering from mild to moderate Dry Eye Syndrome (DES).